FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/28/14 - 20140242082 - Combination therapy for the treatment of ocular neovascular disorders
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention...

08/28/14 - 20140242083 - Anti-mcsp antibodies
The invention provides anti-MCSP antibodies and methods of using the same....

08/28/14 - 20140242084 - Angiopoietin-like 4 and its use in modulating cell leakiness
Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated...

08/28/14 - 20140242085 - Methods and composition for testing, preventing, and treating aspergillus fumigatus infection
As a result of the analysis by an SST-REX method so as to identify a target molecule for treating and testing an Aspergillus fumigatus infection, a YMAF1 protein has been found out, which is mainly localized in the cell wall of Aspergillus fumigatus. Moreover, it has been found out that...

08/28/14 - 20140242086 - Polynucleotides encoding signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP....

08/21/14 - 20140234319 - Treatment of heart failure and related conditions
Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGFβ1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGFβ1 activity in heart failure. The...

08/21/14 - 20140234320 - Modulators of 4-1bb and immune responses
The invention provides peptides and fragments, methods and uses based upon modulating the binding or interaction between 4-1BB and galectins such as Galectin-9. Modulating such binding or interaction between 4-1BB and a galectin, such as Galectin 9. modulates an immune response....

08/21/14 - 20140234321 - Hunk, a snf1-related kinase essential for mammary tumor metastasis
This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the role of HUNK in tumor metastasis, primary tumor development, and the prediction of tumor behavior....

08/21/14 - 20140234322 - Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein...

08/21/14 - 20140234323 - Compositions and methods for detecting tlr3
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same;...

08/21/14 - 20140234324 - Methods for treating a tumor using an antibody that specifically binds grp94
Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses...

08/21/14 - 20140234325 - Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal...

08/21/14 - 20140234326 - Method for decreasing radioresistance and growth, metastasis and infiltration of cancer cells through regulating expression or activity of tm4sf4 in non-small cell lung cancer
The present invention relates to a pharmaceutical composition or an anticancer agent for preventing and treating non-small cell lung cancer, containing a substance for regulating the expression or activity of transmembrane 4 L six family member 4 (TM4SF4). More specifically, the present invention relates to a use of a substance...

08/14/14 - 20140227274 - Prevention and treatment of amyloidogenic disease
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is...

08/14/14 - 20140227275 - Methods of treating and diagnosing pancreatitis
The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2,...

08/14/14 - 20140227276 - Gpr177 as target and marker in tumors
The present invention relates to modulators of G protein-coupled receptor 177 (Gpr177) for use in the treatment, alleviation, prevention and/or diagnosis of cancer as well as to methods for the diagnosis of such cancer....

08/14/14 - 20140227277 - Combination therapy with an anti-cd19 antibody and a purine analog
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia....

08/14/14 - 20140227278 - Antibodies to human signal peptide-containing proteins
The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP....

08/14/14 - 20140227279 - Methods and compositions for the treatment of autoimmune and inflammatory diseases
Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed....

08/14/14 - 20140227280 - Protein complex comprising mcm8 and mcm9 proteins and their use
The composition includes either an isolated protein complex including MCM8 and MCM9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility....

08/14/14 - 20140227281 - Methods of treating herpesvirus infections
The present disclosure provides methods for the prevention or treatment of herpes virus infections. The pharmaceutical composition contains a substance inhibiting the binding of glycoprotein B to a non-muscle myosin heavy chain IIA or IIB....

08/07/14 - 20140220022 - Pthrp, its isoforms and antagonist thereto in the diagnosis and treatment of disease
The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform...

08/07/14 - 20140220023 - Method of treating osteoarthritis with an antibody to ngf
Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved....

08/07/14 - 20140220024 - Chymase compositions, antibodies, diagnostics, and therapeutic methods related thereto
The disclosure relates to chymase, antibodies to chymase, and diagnostic and therapeutic methods relates thereto. It has been discovered that above certain circulating levels of chymase, a patient has a high likelihood of AVF nonmaturation. Compositions and methods of detecting and measuring chymase levels are disclosure herein. In certain embodiments,...

08/07/14 - 20140220025 - Novel stip1 polypeptides and uses thereof
The present invention is directed toward pharmaceutical compositions comprising an isolated polypeptide and a pharmaceutically acceptable carrier. The present invention also discloses an antibody or an antigen-binding portion thereof that bind to the isolated polypeptide. Methods of inhibiting cancer cells growth are also disclosed, comprising administering the isolated polypeptide or...

08/07/14 - 20140220026 - Therapeutic use of specific ligand in msrv associated diseases
A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as...

08/07/14 - 20140220027 - 1d05 pcsk9 antagonists
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host...

08/07/14 - 20140220028 - Antibodies directed against signal peptides, methods and uses thereof
Provided are methods employing antibodies directed against the signal peptide (SP) domain of various disease-associated polypeptides. These anti-SP antibodies detect cell surface expression of these SP domains and are used in methods of diagnosis and/or therapy. Provided is a method for determining the suitability for treatment of a subject suffering...

07/31/14 - 20140212426 - Toll-like receptor 3 antagonists
Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed....

07/31/14 - 20140212427 - Anti-properdin antibodies and uses thereof
This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-properdin antibody. Specifically, the invention relates to methods of treating an AP-mediated pathology or AP-mediated condition in an individual by contacting the individual with an anti-properdin antibody....

07/31/14 - 20140212428 - Human il-23 antigen binding proteins
Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided....

07/31/14 - 20140212429 - Binding members-513
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a KD of 10 pM or less when measured by Kinexa™. The...

07/24/14 - 20140205605 - Optimized antibodies that target hm1.24
The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an FcγR or alters effector function as compared...

07/24/14 - 20140205606 - Anti c-met antibodies
The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein....

07/24/14 - 20140205607 - Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Antibody VRC01 represents a human immunoglobulin that neutralizes—˜90% of diverse HIV-1 isolates. To understand how such broadly neutralizing HIV-1 antibodies develop and recognize the viral envelope, we used X-ray crystallography and 454 pyrosequencing to characterize additional antibodies from HIV-1-infected individuals. Crystal structures revealed a convergent mode of binding of different...

07/24/14 - 20140205608 - Use of c-fms antagonists
The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that...

07/17/14 - 20140199313 - Process for the production of fine chemicals
The present invention relates to a process for the production of the fine chemical in a microorganism, a plant cell, a plant, a plant tissue or in one or more parts thereof, preferably in plastids. The invention furthermore relates to nucleic acid molecules, polypeptides, nucleic acid constructs, vectors, antibodies, host...

07/17/14 - 20140199314 - Methods and compositions for regulating iron homeostasis by modulation of bmp-6
Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation....

07/17/14 - 20140199315 - Sp35 antibodies and uses thereof
Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of...

07/17/14 - 20140199316 - Methods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of MPO inhibitors and inhibitors of MPO and E-selectin binding. In some embodiments, methods are provided for treating G-CSF-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits E-selectin receptor/ligand interaction or inhibits MPO...

07/17/14 - 20140199317 - Actriia binding agents and uses thereof
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same....

07/17/14 - 20140199318 - Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia....

07/10/14 - 20140193417 - Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to...

07/10/14 - 20140193418 - Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD....

07/10/14 - 20140193419 - Methods and compositions for treating and diagnosing diseases
Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in...

07/10/14 - 20140193420 - Diagnosis and treatment of cancer using anti-itm2a antibody
Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a...

07/10/14 - 20140193421 - Anti-human xcr1 antibodies
An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and...

07/03/14 - 20140186357 - Method for treatment of degenerative brain disorders comprising inhibitor of sum01 and bace1 interaction as an active ingredient
A treatment method for degenerative brain disorders using a pharmaceutically effective dose of the inhibitor of SUMO1 (small ubiquitin-like modifier 1) and BACE1 (β-secretase) interaction, or the inhibitor of SUMO1 expression or activation is provided. More specifically, it was confirmed that SUMO1 increased BACE1 accumulation and Aβ generation, that is...

07/03/14 - 20140186358 - Her3 antibodies binding to the beta-hairpin of her3
The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament....

07/03/14 - 20140186359 - Pharmaceutical composition for treatment and/or prophylaxis of cancer
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide...

06/26/14 - 20140178390 - Biological materials related to cxcr7
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present...

06/26/14 - 20140178391 - Colon disease targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as...

06/26/14 - 20140178392 - Nogo receptor-mediated blockade of axonal growth
Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in...

06/26/14 - 20140178393 - Amino acid sequence presenting fusion polypeptide and its use
Herein is reported a fusion polypeptide according to formula (I): NH2—S2—X1—S1—COOH, wherein X1 comprises either a random amino acid sequence or an amino acid sequence derived from a first polypeptide, S2 and S1 are non-overlapping amino acid sequences derived from a second polypeptide, and denotes a peptide bond, wherein the...

06/26/14 - 20140178394 - Novel antigen peptide and uses thereof
The invention relates to antigen peptide derived from the Nectin4 and its use for preventing and treating cancer....

06/26/14 - 20140178395 - Treatment of nephropathy
The present invention relates to treatment of nephropathy. In particular, the present invention relates to treatment of nephropathy using therapeutic antibodies....

06/26/14 - 20140178396 - Treatment of cardiovascular diseases
The present invention relates to treatment of cardiovascular diseases and arthero-sclerosis. In particular, the present invention relates to use of therapeutic antibodies....

06/26/14 - 20140178397 - Anti-angiogenic therapy
The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis....